Tempus AI's Cardiology Breakthrough Validates Expansion Beyond Oncology

Tempus AI's clinical trial with Medtronic proves its tech accelerates cardiac care. Q4 revenue surged 83% as the company expands from oncology into a major new market.

A landmark clinical trial conducted in partnership with medical device giant Medtronic has demonstrated that Tempus AI's technology can deliver significant value in cardiology, marking a critical expansion from its core oncology focus. The study results prove that the company's artificial intelligence platform can meaningfully accelerate care for patients with severe heart conditions, opening access to a substantial new market.

Strategic Validation Through Clinical Data

The ALERT study, which involved 35 U.S. hospitals, evaluated the impact of Tempus AI's "Tempus Next" platform. By employing natural language processing (NLP) to scan patient records in real time, the system identifies clinically relevant findings. The data revealed that patients in the AI-assisted group were 27% more likely to receive a necessary specialist evaluation within 90 days.

The effect was even more pronounced for life-saving heart valve procedures, where the intervention group saw a 40% increase compared to standard care pathways. This outcome represents a strategic milestone for Tempus AI, as its platform-agnostic design allows for standardized care protocols across hardware from different manufacturers, a key feature for hospital systems and payers.

Financial Performance and Forward Guidance

This clinical validation coincides with robust operational momentum. The company reported fourth-quarter 2025 revenue of approximately $367 million, an increase of 83% year-over-year. Its diagnostics segment was the primary growth driver, surging by over 120%.

Despite recent gains of around 10% over a weekly period, the equity, trading at €41.00, remains well below its 52-week high of €89.00.

Management has set ambitious targets for the current fiscal year:
- 2026 Revenue Forecast: $1.59 to $1.60 billion
- Adjusted EBITDA: Approximately $65 million
- Liquid Assets (end of 2025): $759.7 million

Investors will be closely watching the first-quarter 2026 financial results, scheduled for release on May 5, 2026, for updates on the scaling of cardiology applications and net revenue profitability. The core competitive advantage—leveraging real-world data to speed up clinical decision-making—continues to be central to forging new partnerships.